Palboxen 125 mg is identified on this website as a product containing palbociclib, an anticancer medicine belonging to a group of medicines known as cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. Palbociclib is used in specified breast cancer treatment settings, particularly hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer, in combination with appropriate endocrine therapy.
Palbociclib works by blocking two proteins, CDK4 and CDK6, which help regulate cell division. In certain cancer cells, these proteins contribute to uncontrolled cell growth. By inhibiting CDK4 and CDK6, palbociclib can interfere with the cell cycle and slow the multiplication of cancer cells.
Palboxen is identified in the supplied product information as a 125 mg palbociclib product associated with Everest. Product-specific details, including the precise dosage form, manufacturing site and applicable marketing authorization, should be confirmed using the actual product packaging and official documentation.
Palbociclib is an oral targeted anticancer medicine. It is classified as a CDK4/6 inhibitor because it selectively inhibits cyclin-dependent kinases 4 and 6.
These proteins are involved in controlling the transition of cells from the G1 phase to the S phase of the cell cycle. The S phase is when a cell copies its DNA before dividing. In susceptible cancer cells, CDK4 and CDK6 activity can contribute to abnormal cell proliferation.
Palbociclib interferes with this process. It is commonly used alongside endocrine medicines because hormone receptor-positive breast cancer may depend on estrogen signaling as well as cell-cycle pathways for continued growth.
Palbociclib is not a general treatment for every type of breast cancer. Its suitability depends on the cancer’s receptor status, stage, previous treatment, the patient’s overall health and the applicable treatment guidelines.
Palbociclib is used in selected treatment regimens for advanced or metastatic breast cancer. A principal treatment setting is HR-positive, HER2-negative disease.
It is generally prescribed in combination with endocrine therapy, such as:
An aromatase inhibitor in an appropriate treatment setting.
Fulvestrant in an appropriate treatment setting.
Other endocrine treatment combinations only where supported by the applicable product authorization and clinical guidance.
For premenopausal or perimenopausal women, ovarian suppression with a gonadotropin-releasing hormone (GnRH) agonist may also be required as part of the treatment plan.
The exact approved indications can differ between countries and may change as regulatory authorities review new clinical evidence. Patients should follow the indication approved in their country and the advice of their oncology team.
Palbociclib targets CDK4 and CDK6, two proteins involved in cell-cycle regulation.
Under normal conditions, cyclin D proteins interact with CDK4 and CDK6. These complexes help regulate the retinoblastoma protein, commonly called Rb. When Rb is phosphorylated, cells can progress from the G1 phase into the S phase of the cell cycle.
Palbociclib inhibits CDK4 and CDK6 activity. This reduces Rb phosphorylation and can prevent susceptible cancer cells from progressing through the cell cycle. The result is cell-cycle arrest, which may slow the growth and multiplication of cancer cells.
This targeted action is different from the way traditional chemotherapy works. However, palbociclib can still cause significant adverse effects, especially a reduction in neutrophils, a type of white blood cell that helps the body fight infection.
Product information | Details |
|---|---|
Product name | Palboxen |
Generic name | Palbociclib |
Stated strength | 125 mg |
Drug category | Anticancer medicine |
Drug class | CDK4/6 inhibitor |
Main treatment area | Selected advanced or metastatic breast cancer |
Principal receptor profile | HR-positive, HER2-negative |
Route of administration | Oral, subject to confirmation of the specific product |
Company stated in supplied information | Everest |
Dosage form | Requires confirmation from product packaging |
Regulatory status | Requires confirmation for the relevant country |
The 125 mg strength is a recognized palbociclib treatment strength. In commonly used reference-product regimens, the standard starting schedule is one prescribed dose daily for 21 consecutive days, followed by 7 days without treatment. These 28 days make up one treatment cycle.
However, the 125 mg strength should not be interpreted as the correct dose for every patient. A specialist may prescribe a lower dose or interrupt treatment when blood counts or other safety findings require an adjustment.
Dose decisions must be based on the applicable prescribing information and the patient’s clinical condition.
Palbociclib is usually taken once daily according to a repeating treatment schedule. The reference regimen commonly uses:
Days 1–21: prescribed daily palbociclib dose.
Days 22–28: treatment break.
Day 29: beginning of the next cycle, if the oncology team confirms treatment should continue.
The treatment break allows time for blood-cell counts, particularly neutrophils, to recover.
The exact administration instructions depend on the formulation. Reference palbociclib capsules and tablets have different food instructions: capsules are taken with food, while tablets may be taken with or without food under the applicable reference-product labeling. The formulation of Palboxen must be confirmed before giving product-specific food instructions.
Patients should not change their dose, extend the treatment break or restart treatment without guidance from their oncology team.
Palbociclib can cause side effects. Their severity and frequency vary between individuals and may depend on the treatment combination.
Commonly reported adverse effects include:
Neutropenia, meaning a reduced number of neutrophils.
Low white blood cell counts.
Anemia.
Thrombocytopenia, or reduced platelet counts.
Fatigue.
Nausea.
Diarrhea.
Mouth sores or inflammation of the mouth.
Reduced appetite.
Hair thinning or hair loss.
Infections.
Changes in liver blood-test results.
Neutropenia is particularly important because it can increase the risk of infection. Regular blood tests are therefore an essential part of treatment.
Palbociclib should be used under the supervision of an oncologist or another qualified cancer specialist.
Before treatment begins, the healthcare professional should review the patient’s medical history, current medicines, blood-test results and other relevant health information.
Important precautions include:
Blood-cell monitoring: Complete blood counts are required before treatment and at specified intervals during therapy. Monitoring is particularly important during the first treatment cycles and whenever dose adjustments are made.
Infection risk: Patients should report fever, chills, persistent cough, sore throat or other possible signs of infection promptly.
Liver function: Liver-related blood tests may be required during treatment, particularly if there are symptoms or laboratory findings suggesting liver injury.
Lung symptoms: Rare cases of interstitial lung disease or pneumonitis have been reported with CDK4/6 inhibitors, including palbociclib. New or worsening breathlessness, cough or other unexplained respiratory symptoms require prompt medical assessment.
Drug interactions: Certain medicines can change palbociclib exposure in the body. Strong CYP3A inhibitors and strong CYP3A inducers are particularly important. Patients should tell their healthcare professional about prescription medicines, non-prescription medicines, supplements and herbal products.
Pregnancy and breastfeeding: Palbociclib may cause fetal harm. Pregnancy prevention and breastfeeding precautions should be discussed with the treating specialist.
Palbociclib treatment requires more than taking a medicine every day. The oncology team must assess treatment response, monitor blood counts, review side effects and decide whether treatment should continue, be interrupted or be reduced.
A low neutrophil count may require a temporary treatment interruption or dose modification. Patients should not restart treatment automatically after a break if their healthcare professional has instructed them to wait for blood-test results.
Treatment decisions also depend on the endocrine medicine used with palbociclib and the patient’s previous cancer treatment.
Palboxen.com is intended to provide educational and product-related information about Palboxen 125 mg and its active ingredient, palbociclib.
The website aims to explain the medicine’s therapeutic role, mechanism of action, treatment schedule, safety precautions, possible side effects and product-identification considerations in accessible language.
The information is not a substitute for professional medical advice, diagnosis or treatment. The website does not determine whether palbociclib is appropriate for an individual patient.
The information on this page is provided for educational purposes only. It does not replace an oncologist’s advice or the official prescribing information applicable to the specific product and country.
Patients must not start, stop or change palbociclib treatment without medical guidance.
No posts found.
Palbociclib is not generally associated with significant changes in kidney function in most patients. However, kidney health and overall medical condition should be assessed before treatment. Patients with severe kidney impairment should receive specialist evaluation to determine the appropriate treatment approach.
Grapefruit and grapefruit juice may affect CYP3A enzymes and increase palbociclib exposure in the body. Patients should avoid grapefruit products during treatment according to the applicable prescribing information and discuss dietary precautions with their healthcare professional.
The effects of palbociclib on human fertility are not fully established. Patients who may wish to have children in the future should discuss potential fertility concerns and preservation options with their oncology team before beginning treatment.
Palbociclib does not necessarily prevent patients from driving. However, fatigue, dizziness or other treatment-related symptoms may affect concentration and alertness. Patients should avoid driving if they feel unwell or unable to drive safely.
Changes in cholesterol levels are not among the principal characteristic adverse effects of palbociclib. However, patients should continue any recommended health assessments and discuss abnormal laboratory results with their healthcare professional.
Inform your oncologist and surgical team that you are taking palbociclib before undergoing surgery or an invasive procedure. Your healthcare team may consider blood counts, infection risk, wound healing and the timing of treatment when deciding whether a temporary interruption is appropriate.
Palbociclib can affect the bone marrow and reduce neutrophil levels, which may weaken the body's ability to fight infections. Patients should follow medical monitoring instructions and report symptoms of infection promptly.
Vaccination decisions should be discussed with the treating healthcare professional. Live vaccines may be unsuitable during treatment because of potential immune-related risks. The timing and suitability of non-live vaccines should also be assessed according to the patient's condition and vaccination guidance.
Some patients receiving cancer treatment may experience changes in taste or appetite. If food tastes different, eating becomes difficult, or weight loss occurs, inform your healthcare professional so that nutritional support can be considered.
Unusual bruising or bleeding may indicate a reduced platelet count or another medical problem. Contact your healthcare professional for assessment and possible blood testing. Severe or uncontrolled bleeding requires urgent medical attention.
Palbociclib is not primarily a dehydrating medicine, but side effects such as diarrhea, nausea or vomiting may contribute to fluid loss. Patients should maintain appropriate fluid intake unless medically restricted and report persistent gastrointestinal symptoms.
Some antibiotics can interact with palbociclib. Certain antibiotics, particularly strong CYP3A inhibitors, may increase palbociclib levels. Always inform your doctor or pharmacist before starting an antibiotic so that potential interactions can be reviewed.
If blood counts become significantly reduced, the oncologist may temporarily interrupt treatment, delay the next cycle or reduce the dose. The decision depends on the severity of the abnormality, symptoms and laboratory results. Patients should not adjust treatment independently.
The healthcare team assesses treatment effectiveness through clinical evaluation, symptom review and appropriate imaging studies. The frequency and type of assessment depend on the patient's cancer, treatment plan and clinical response.
Provide your doctor with information about your medical history, previous cancer treatments, allergies, liver and kidney conditions, current medicines, supplements, pregnancy plans and any history of infections. This information helps the healthcare professional assess whether palbociclib is appropriate and establish a suitable monitoring plan.